Taisho Pharmaceutical Ind (SQBI_p)

Jakarta

Currency in IDR

440,000

0(0.00%)

Closed04/02

Fair Value

Day's Range

440,000

440,000

52 wk Range

0

440,000

SQBI_p Income Statement

Explore the detailed Taisho Pharmaceutical Ind income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Taisho Pharmaceutical Ind's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

703,665.16

542,095.32

668,841.2

790,151.29

550,973.01

Total Revenues Growth

+6.22%

-22.96%

+23.38%

+18.14%

-30.27%

Cost Of Revenues

250,426.5

189,848.85

227,746.15

317,466.67

349,431.39

Gross Profit

453,238.66

352,246.47

441,095.05

472,684.62

201,541.62

Gross Profit Growth

+18.67%

-22.28%

+25.22%

+7.16%

-57.36%

Gross Profit Margin %

64.41%

64.98%

65.95%

59.82%

36.58%

Other Operating Expenses, Total

154,042.74

106,230.58

159,355.12

168,085.38

111,828.02

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+17.9%	-31.04%	+50.01%	+5.48%	-33.47%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	156,417.71	113,004.21	171,319.86	180,175.99	121,278.46
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-2,374.97	-6,773.63	-11,964.74	-12,090.61	-9,450.44

Operating Income

299,195.92

246,015.89

281,739.93

304,599.24

89,713.6

Operating Income Growth

+19.07%

-17.77%

+14.52%

+8.11%

-70.55%

EBIT Margin %

42.52%

45.38%

42.12%

38.55%

16.28%

Net Interest Expenses

3,601.12

2,153.09

3,321.84

7,342.54

13,621.65

Net Interest Expenses Growth

+221.04%

-40.21%

+54.28%

+121.04%

+85.52%

Interest Expense, Total

-

-190.7

-320.05

-493.75

-376.67

Interest And Investment Income

3,601.12

2,343.79

3,641.88

7,836.29

13,998.31

Other Non Operating Expenses, Total

-1,798.32

1,718

-195.17

8,292.02

-1,016.07

EBT, Excl. Unusual Items

300,998.72

249,886.98

284,866.6

320,233.8

102,319.18

Gain (Loss) On Sale Of Assets

-125.13

-

-346.93

69.94

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

300,873.59

249,886.98

284,519.67

320,303.74

102,319.18

EBT, Incl. Unusual Items Growth

+17.68%

-16.95%

+13.86%

+12.58%

-68.06%

EBT, Incl. Unusual Items Margin

42.76%

46.1%

42.54%

40.54%

18.57%

Income Tax Expense

74,852.7

79,929.75

64,396.17

69,985.29

21,633.63

Net Income to Company

226,020.88

169,957.22

220,123.5

250,318.45

80,685.55

Minority Interest

-

-

-

-

-

Net Income

226,020.88

169,957.22

220,123.5

250,318.45

80,685.55

Net Income Growth

+17.9%

-24.8%

+29.52%

+13.72%

-67.77%

Net Income Margin %

32.12%

31.35%

32.91%

31.68%

14.64%

Preferred Dividend and Other Adjustments

15,527.67

17,979.41

17,979.41

17,979.41

17,979.41

Net Income to Common Excl. Extra Items

210,493.21

151,977.81

202,144.08

232,339.04

62,706.14

Basic EPS - Continuing Operations

22,711.83

16,398.12

21,810.97

25,068.95

6,765.88

Basic EPS - Continuing Operations Growth

+20.58%

-27.8%

+33.01%

+14.94%

-73.01%

Diluted EPS - Continuing Operations

22,711.83

16,390

21,810.97

25,068.95

6,765.88

Diluted EPS - Continuing Operations Growth

+20.58%

-27.83%

+33.07%

+14.94%

-73.01%

Basic Weighted Average Shares Outstanding

9.27

9.27

9.27

9.27

9.27

Diluted Weighted Average Shares Outstanding

9.27

9.27

9.27

9.27

9.27

Dividend Per Share

22,000

-

-

-

-

Dividend Per Share Growth

+15.79%

-

-

-

-

EBITDA

314,077.46

262,126.78

299,051.14

324,749.56

109,488.12

EBITDA Growth

+18.03%

-16.54%

+14.09%

+8.59%

-66.29%

EBITDA Margin %

44.63%

48.35%

44.71%

41.1%

19.87%

EBIT